Payment overview · 2025
General Payments
$638.67
36 reported records · 15 companies
Healthcare provider profile · identity verified
Lori A Blackburn, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · MORRISTOWN, TN · NPI 1780791749
Verified facts
What the public records show
CMS Open Payments records show Lori A Blackburn, PAC received $638.67 in general payments during 2025 across 36 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $136.30 | 21.3% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.08 | 15.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.66 | 7.8% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $41.76 | 6.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $41.54 | 6.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.35 | 6.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.46 | 5.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.37 | 5.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.59 | 4.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.20 | 4.1% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $25.48 | 4.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.74 | 3.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.16 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.82 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.16 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $638.67 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $136.30 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $101.08 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.39 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $41.76 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.37 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.52 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.52 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 252 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
112 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
252 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 870 | 187 |
| Atorvastatin Calcium | Atorvastatin Calcium | 709 | 182 |
| Amlodipine Besylate | Amlodipine Besylate | 447 | 116 |
| Gabapentin | Gabapentin | 412 | 86 |
| Lisinopril | Lisinopril | 384 | 100 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 349 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 341 | 98 |
| Omeprazole | Omeprazole | 317 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 270 | 64 |
| Montelukast Sodium | Montelukast Sodium | 268 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 267 | 80 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 252 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 56 |
| Furosemide | Furosemide | 242 | 69 |
| Potassium Chloride | Potassium Chloride | 204 | 46 |
| Losartan Potassium | Losartan Potassium | 189 | 49 |
| Glimepiride | Glimepiride | 182 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 43 |
| Meloxicam | Meloxicam | 168 | 44 |
| Ozempic | Semaglutide | 167 | 31 |
| Simvastatin | Simvastatin | 166 | 41 |
| Metformin Hcl | Metformin Hcl | 158 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 37 |
| Clonidine Hcl | Clonidine Hcl | 157 | 47 |
| Famotidine | Famotidine | 157 | 29 |
| Atenolol | Atenolol | 153 | 41 |
| Buspirone Hcl | Buspirone Hcl | 151 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 145 | 44 |
| Carvedilol | Carvedilol | 135 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 128 | 37 |
| Lovastatin | Lovastatin | 126 | 25 |
| Allopurinol | Allopurinol | 117 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 26 |
| Prednisone | Prednisone | 116 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 27 |
| Trazodone Hcl | Trazodone Hcl | 113 | 32 |
| Linzess | Linaclotide | 112 | 21 |
| Donepezil Hcl | Donepezil Hcl | 109 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 106 | 21 |
| Clonazepam | Clonazepam | 106 | 24 |
| Spironolactone | Spironolactone | 106 | 21 |
| Trintellix | Vortioxetine Hydrobromide | 106 | 20 |
| Sertraline Hcl | Sertraline Hcl | 105 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 26 |
| Eliquis | Apixaban | 102 | 26 |
| Ibuprofen | Ibuprofen | 99 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 32 |
| Jardiance | Empagliflozin | 93 | 25 |
| Alprazolam | Alprazolam | 92 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 21 |
| Nifedipine Er | Nifedipine | 83 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 20 |
| Xarelto | Rivaroxaban | 77 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 62 |
| Fluconazole | Fluconazole | 74 | 41 |
| Warfarin Sodium | Warfarin Sodium | 74 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 13 |
| Nystatin | Nystatin | 71 | 29 |
| Tramadol Hcl | Tramadol Hcl | 71 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 71 | 21 |
| Baclofen | Baclofen | 68 | 17 |
| Benazepril Hcl | Benazepril Hcl | 68 | 15 |
| Bumetanide | Bumetanide | 68 | 18 |
| Estradiol | Estradiol | 67 | 12 |
| Pregabalin | Pregabalin | 66 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 14 |
| Azithromycin | Azithromycin | 61 | 51 |
| Ezetimibe | Ezetimibe | 60 | 19 |
| Levofloxacin | Levofloxacin | 60 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 16 |
| Farxiga | Dapagliflozin Propanediol | 59 | 14 |
| Methocarbamol | Methocarbamol | 59 | 14 |
| Levetiracetam | Levetiracetam | 57 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 35 |
| Testosterone Cypionate | Testosterone Cypionate | 56 | 12 |
| Fenofibrate | Fenofibrate | 55 | 12 |
| Mirtazapine | Mirtazapine | 55 | 14 |
| Memantine Hcl | Memantine Hcl | 54 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 14 |
| Celecoxib | Celecoxib | 52 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 13 |
| Gemfibrozil | Gemfibrozil | 50 | suppressed |
| Sucralfate | Sucralfate | 49 | 15 |
| Lactulose | Lactulose | 47 | suppressed |
| Myrbetriq | Mirabegron | 47 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 11 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Vraylar | Cariprazine Hcl | 46 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Single Use Swab | Alcohol Antiseptic Pads | 43 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Tradjenta | Linagliptin | 42 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | suppressed |
| Chlorthalidone | Chlorthalidone | 41 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 13 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Diazepam | Diazepam | 40 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | suppressed |
| Acyclovir | Acyclovir | 39 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 11 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Rexulti | Brexpiprazole | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 32 | 25 |
| Divalproex Sodium Er | Divalproex Sodium | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 21 |
| Metronidazole | Metronidazole | 31 | 13 |
| Dexamethasone | Dexamethasone | 30 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 24 |
| Synthroid | Levothyroxine Sodium | 30 | 11 |
| Valsartan | Valsartan | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Cefdinir | Cefdinir | 27 | 23 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 20 |
| Metolazone | Metolazone | 22 | suppressed |
| Nyamyc | Nystatin | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Torsemide | Torsemide | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | 14 |
| Norethindrone Acetate | Norethindrone Acetate | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Levetiracetam Er | Levetiracetam | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Levocarnitine | Levocarnitine | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Qtern | Dapagliflozin/Saxagliptin Hcl | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $638.67 · 36 records | Otsuka America Pharmaceutical, Inc. | Auvelity, CAPLYTA, FANAPT, FARXIGA, GVOKE HYPOPEN, HETLIOZ, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, Kerendia, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, YUPELRI | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error